Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(VICL, ADI, UNH, PWRM.OB, JNPR) Stock Report from

|Includes: Analog Devices Inc. (ADI), JNPR, UNH, VICL




Vical Incorporated (Nasdaq:VICL) reported that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at the BioCentury/Thomson Reuters NewsMakers in the Biotech Industry Conference (New York, October 22; presentation at 10:30 a.m. ET).

A webcast of Mr. Samant's presentation will be available live and archived through the Events page in the Investors section of VICL's website.


Analog Devices Inc. (NYSE: ADI) Standard & Poor's Ratings Services raised its long-term corporate credit and senior unsecured ratings on chipmaker Analog Devices Inc. Wednesday September 29, 2010.

ADI recently forecasted fourth-quarter earnings of 68 cents to 72 cents per share on revenue of $740 million to $770 million, well above the earnings of 61 cents per share on revenue of $715.5 million that analysts had expected.

ADI engages in the design, manufacture, and marketing of analog, mixed-signal, and digital signal processing integrated circuits used in industrial, communication, computer, and consumer applications. The company's products convert real-world phenomena, such as light, sound, temperature, motion, and pressure into electrical signals.


Unitedhealth Group, Inc. (NYSE: UNH) plans to lay off 115 workers at an office in Huntingdon Valley, Pa., effective Nov. 15, according to a filing with the Pennsylvania Department of Labor and Industry.

The positions are being eliminated at a prescription mail-service unit UNH of Minneapolis acquired as part of its $775 million purchase of Fiserv Inc.’s health businesses three years ago.
The services provided at the Byberry Road facility that is closing will be handled by other offices of Prescription Solutions, a UnitedHealth subsidiary that provides mail order pharmacy services.


power3 PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

** PWRM delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii.

These presentations discussed NuroPro®, PWRM’s diagnostic test, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, PWRM’s President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

More about PWRM at


Juniper Networks, Inc. (NYSE: JNPR) has joined the board of the Climate Savers Computing Initiative, a non-profit organization dedicated to reducing power consumption in information and communications technology (ICT). Existing industry-leading members of the initiative have worked to increase the adoption of energy-efficient PCs and servers and increase awareness and use of computer power management. JNPR joins Climate Savers Computing to help expand the scope of the initiative to the network.

JNPR is in the business of network innovation. From devices to data centers, from consumers to cloud providers, JNPR delivers the software, silicon and systems that transform the experience and economics of networking. JNPR serves customers and partners worldwide, generating revenues exceeding $3 billion over the last year.


Signup for FREE Daily Stock Alerts From


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM)